| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | VX-147 | |
| 3 | Generic | inaxaplin | |
| 4 | Indication | APOL1-mediated kidney disease, 100k patients US+EU | |
| 5 | MOA | APOL1 inhibitor | |
| 6 | Clinical Trials | ||
| 7 | Phase II/III n=400 proteinuric kidney disease with two APOL1 mutations | ||
| 8 | PE of Phase III portion is 2 year eGFR slope | ||
| 9 | interim analysis at 1 year |